• 上海同濟(jì)大學(xué)附屬東方醫(yī)院普外一病區(qū)(上海200120);

目的提高CEA診斷消化道惡性腫瘤的特異性。
方法采用ELISA法分別測定消化道良、惡性疾病患者血液、消化液（膽汁、胃液）中CEA含量，進(jìn)一步應(yīng)用Western blot半干轉(zhuǎn)移技術(shù)區(qū)分CEA及CEA相關(guān)物質(zhì)。
結(jié)果消化道惡性腫瘤患者消化液中CEA水平明顯高于血液中CEA水平（P＜0.01），消化道良性疾病患者消化液中CEA水平與血液中CEA水平相比差異無統(tǒng)計學(xué)意義； 消化道惡性腫瘤患者消化液中CEA水平明顯高于消化道良性疾病患者消化液中CEA水平（P＜0.01），消化道惡性腫瘤患者血液中CEA水平亦明顯高于消化道良性疾病患者血液中CEA水平（P＜0.05）。除4例CEA含量過低（＜5 μg/L）者外所有消化道惡性腫瘤患者消化液經(jīng)Western blot檢測均表現(xiàn)出一條相對分子質(zhì)量為210×103的特異條帶，而消化道良性疾病患者消化液中均不含有該條帶。
結(jié)論采用消化液并結(jié)合Western blot技術(shù)可提高CEA診斷消化道惡性腫瘤的特異性。

引用本文： 所廣軍,張輝,趙中辛. 用Western blot法區(qū)分膽道、胃部疾病癌胚抗原及其相關(guān)物質(zhì)的研究. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(2): 208-210. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Uchino R, Kanemitsu K, Obayashi H, et al. Carcinoembryonic antigen (CEA) and CEArelated substances in the bile of patients with biliary diseases [Ｊ]. Am J Surg, 1994; 167(3)∶306.
2. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications [Ｊ]. Proc Natl Acad Sci USA, 1979; 76(9)∶4350.
3. Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma [Ｊ]. Am J Surg, 1996; 171(1)∶147.
4. Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 199, and CA 724 in the followup of patients with resectable gastric cancer [Ｊ]. Am J Surg, 2001; 181(1)∶16.
5. Duraker N, Naci Celik A, Gencler N. The prognostic significance of gastric juice CA 199 and CEA levels in gastric carcinoma patients [Ｊ]. Eur J Surg Oncol, 2002; 28(8)∶844.
6. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 199 and carcinoembryonic antigen (CEA) in pancreatic cancer [Ｊ]. Hepatogastroenterology， 2003; 50(53)∶1669.
7. Muretto P, Graziano F, Staccioli MP, et al. An endogastric capsule for measuring tumor markers in gastric juice: an evaluation of the safety and efficacy of a new diagnostic tool [Ｊ]. Ann Oncol, 2003; 14(1)∶105.
  1. 1. Uchino R, Kanemitsu K, Obayashi H, et al. Carcinoembryonic antigen (CEA) and CEArelated substances in the bile of patients with biliary diseases [Ｊ]. Am J Surg, 1994; 167(3)∶306.
  2. 2. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications [Ｊ]. Proc Natl Acad Sci USA, 1979; 76(9)∶4350.
  3. 3. Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma [Ｊ]. Am J Surg, 1996; 171(1)∶147.
  4. 4. Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 199, and CA 724 in the followup of patients with resectable gastric cancer [Ｊ]. Am J Surg, 2001; 181(1)∶16.
  5. 5. Duraker N, Naci Celik A, Gencler N. The prognostic significance of gastric juice CA 199 and CEA levels in gastric carcinoma patients [Ｊ]. Eur J Surg Oncol, 2002; 28(8)∶844.
  6. 6. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 199 and carcinoembryonic antigen (CEA) in pancreatic cancer [Ｊ]. Hepatogastroenterology， 2003; 50(53)∶1669.
  7. 7. Muretto P, Graziano F, Staccioli MP, et al. An endogastric capsule for measuring tumor markers in gastric juice: an evaluation of the safety and efficacy of a new diagnostic tool [Ｊ]. Ann Oncol, 2003; 14(1)∶105.